Vigil Neuroscience Inc. CEO Ivana Magovčević-Liebisch said the just-raised $90 million in series B money will let the company reach “a lot of value-generating milestones,” having been “moving extremely fast” in the year since it was founded.
Immunitas Therapeutics Inc., a company leveraging single cell analysis to identify and validate new drug targets, has closed $58 million in series B financing led by Agent Capital. The funds will be used to advance its lead program, the CD161 inhibitor IMT-009, into the clinic for testing against both solid tumors and hematological malignancies, pending approval of a forthcoming IND filing next year.
Jnana Therapeutics Inc. closed a $50 million series B round and took the covers off its lead program, a small-molecule inhibitor of the solute carrier transporter SLC6A19, which it is prepping for clinical trials in phenylketonuria (PKU).
DUBLIN – Beckley Psytech Ltd. raised $80 million in an oversubscribed series B round to move its early stage pipeline of psychedelic therapies into the clinic and to continue research on novel compounds with enhanced properties.
RSS
